Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
P.CaffreyR.MarioneauxJ.SanthekadurP
Wegovy and Zepbound moved GLP-1 therapy into chronic weight management, creating a direct challenge to older anti-obesity drugs that often delivered limited efficacy or poor tolerability
GLP-1 for sleep apnea, alcohol use and cancer risk GLP-1s may address conditions well beyond metabolic diseases: Obstructive sleep apnea: Emerging data suggest GLP-1s improve apnea symptoms. Alcohol use disorder: Patients using liraglutide or semaglutide reduced alcohol consumption by nearly two-thirds. Obesity-related cancers: An observational study of 6,000 adults found that GLP-1 receptor agonists halved the risk of obesity-related cancers compared with usual care
Liver supplements can be expensive, especially when given long-term
Based on its mechanism of improving insulin sensitivity and promoting fat oxidation, MOTS-c has a strong theoretical potential to support weight loss, particularly fat loss
These SCFAs bind to L-cell receptors, stimulating the release of GLP-1 and promoting glucose metabolism
